Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Adagene (Nasdaq: ADAG), a pioneer in antibody-based therapies, has announced its upcoming presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The presentation, titled 'ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance', is scheduled for 11:30 AM - 11:50 AM Eastern Time at the Sheraton Boston Hotel.
The summit brings together pharmaceutical companies, biotech firms, academia, and investors focused on advancing cancer immunotherapy treatments. The presentation will be held in Track 2, Back Bay Ballroom AB, with slides becoming available on the company's website afterward.
Adagene (Nasdaq: ADAG), pioniere nelle terapie basate su anticorpi, ha annunciato la sua prossima presentazione al 11° Summit Annuale Immuno-Oncology 360⁰ che si terrà a Boston il 26 marzo 2025. La presentazione, intitolata 'ADG126 SAFEbody®: Mirare ai Tregs CTLA-4+ per Superare la Resistenza CRC MSS', è programmata per le 11:30 - 11:50 ora orientale presso lo Sheraton Boston Hotel.
Il summit riunisce aziende farmaceutiche, aziende biotecnologiche, accademici e investitori focalizzati sull'avanzamento dei trattamenti di immunoterapia per il cancro. La presentazione si terrà nella Track 2, Back Bay Ballroom AB, con le diapositive che saranno disponibili sul sito web dell'azienda successivamente.
Adagene (Nasdaq: ADAG), pionero en terapias basadas en anticuerpos, ha anunciado su próxima presentación en el 11° Cumbre Anual de Inmuno-Oncología 360⁰ en Boston el 26 de marzo de 2025. La presentación, titulada 'ADG126 SAFEbody®: Apuntando a Tregs CTLA-4+ para Superar la Resistencia CRC MSS', está programada para las 11:30 - 11:50 hora del Este en el Sheraton Boston Hotel.
La cumbre reúne a empresas farmacéuticas, firmas biotecnológicas, académicos e inversores enfocados en avanzar en tratamientos de inmunoterapia contra el cáncer. La presentación se llevará a cabo en la Track 2, Back Bay Ballroom AB, con las diapositivas disponibles en el sitio web de la empresa posteriormente.
Adagene (Nasdaq: ADAG), 항체 기반 치료의 선구자로, 2025년 3월 26일 보스턴에서 열리는 제11회 연례 면역-종양학 360⁰ 정상 회담에서의 발표를 발표했습니다. 'ADG126 SAFEbody®: CTLA-4+ Tregs를 겨냥하여 MSS CRC 저항 극복하기'라는 제목의 발표는 동부 표준시 기준으로 오전 11시 30분부터 11시 50분까지 Sheraton Boston Hotel에서 진행될 예정입니다.
이번 정상 회담은 암 면역 치료 발전에 집중하는 제약 회사, 생명공학 회사, 학계 및 투자자들을 모읍니다. 발표는 Track 2, Back Bay Ballroom AB에서 진행되며, 이후 회사 웹사이트에서 슬라이드를 확인하실 수 있습니다.
Adagene (Nasdaq: ADAG), pionnier dans les thérapies basées sur les anticorps, a annoncé sa prochaine présentation lors du 11e Sommet Annuel Immuno-Oncology 360⁰ à Boston le 26 mars 2025. La présentation, intitulée 'ADG126 SAFEbody®: Cibler les Tregs CTLA-4+ pour surmonter la résistance MSS CRC', est prévue de 11h30 à 11h50 heure de l'Est à l'hôtel Sheraton Boston.
Le sommet réunit des entreprises pharmaceutiques, des entreprises de biotechnologie, des universitaires et des investisseurs axés sur l'avancement des traitements d'immunothérapie contre le cancer. La présentation se tiendra dans la Track 2, Back Bay Ballroom AB, et les diapositives seront disponibles sur le site web de l'entreprise par la suite.
Adagene (Nasdaq: ADAG), ein Pionier in der Antikörper-basierten Therapie, hat seine bevorstehende Präsentation beim 11. jährlichen Immuno-Oncology 360⁰-Gipfel in Boston am 26. März 2025 angekündigt. Die Präsentation mit dem Titel 'ADG126 SAFEbody®: Zielgerichtete CTLA-4+ Tregs zur Überwindung des MSS CRC-Widerstands' ist für 11:30 - 11:50 Uhr Eastern Time im Sheraton Boston Hotel geplant.
Der Gipfel bringt Pharmaunternehmen, Biotech-Firmen, Akademiker und Investoren zusammen, die sich auf die Weiterentwicklung von Krebsimmuntherapien konzentrieren. Die Präsentation findet in Track 2, Back Bay Ballroom AB statt, und die Folien werden anschließend auf der Website des Unternehmens verfügbar sein.
- None.
- None.
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025.
The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology.
Immuno-Oncology 360⁰ Summit
- Title: ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance
- Date: Wednesday, March 26, 2025
- Time: 11:30 AM - 11:50 AM Eastern Time
- Onsite Location: Sheraton Boston Hotel, Track 2, Back Bay Ballroom AB
Following the presentation, the slides will also be available on the Presentations page of the Company’s website.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor Contacts:
Raymond Tam
Raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com
FAQ
When and where is Adagene (ADAG) presenting at the Immuno-Oncology 360⁰ Summit?
What is the focus of Adagene's (ADAG) presentation at the IO360 Summit 2025?
How can investors access Adagene's (ADAG) IO360 Summit presentation materials?
What is the significance of Adagene's (ADAG) participation in the 2025 IO360 Summit?
